Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Keppra · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Levetiracetam Tablets, 750 mg (Sandoz Inc.) |
| 2 | ACTIVE_COMPARATOR | Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc) |
| Name | Type | Description |
|---|---|---|
| Levetiracetam Tablets, 750 mg (Sandoz Inc.) | DRUG | - |
| Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Keppra is a levetiracetam tablet formulation studied for seizure. The clinical trial referenced in this record enrolled healthy adult volunteers rather than patients with active seizure disorders, and it evaluated the 750 mg tablet under fasting conditions. Keppra is a small molecule in the neurology therapeutic area.
Keppra is associated with Novartis AG, which trades under the ticker NVS. The 750 mg levetiracetam tablet referenced in this record is also identified with UCB Pharma, Inc, and the bioavailability trial compared the Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg levetiracetam tablets.
Keppra is recorded at Phase 1 in this dataset. The single listed trial, NCT00946751, is a Phase 1 study that has been completed, with no active trials currently listed. The study was randomized and used an active control design.
Keppra is referenced in one clinical trial, NCT00946751, titled to demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg levetiracetam tablets in healthy adult volunteers under fasting conditions. The trial is Phase 1, completed, randomized, active controlled, and enrolled 20 participants aged 18 years and older.
Yes, Keppra is a brand name for levetiracetam. The record identifies the asset as Keppra (Levetiracetam) Tablets, 750 mg, from UCB Pharma, Inc. The trial title also refers to the product as 750 mg levetiracetam tablets, confirming that Keppra and levetiracetam refer to the same tablet formulation.